Zifan Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zifan Yang has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Jinshuai Liu
Department of Neurology, the First Affiliated Hospital of Anhui Medical University, Hefei, China
2 shared publicationsDengyuan Hao
State Key Laboratory of Polymer Physics and Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, Jilin, P. R. China
1 shared publicationFengqing Lu
Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui, P. R. China
1 shared publicationHao Yang
School of Basic Medical Sciences, Anhui Medical University, Hefei 230032, Anhui, P. R. China
1 shared publicationJianxiang Lei
Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui, P. R. China
1 shared publicationKehong Zeng
Department of Neurology, the First Affiliated Hospital of Anhui Medical University, Hefei, China; Anhui Public Health Clinical Center, Hefei 230041 Anhui, China
1 shared publication
Latest Publications
- 5 October 2025
- Published by Elsevier in Neuroscience
- Vol. 588, 84-91
Choroid plexus enlargement correlates with cognitive impairment and brain atrophy in patients with temporal lobe epilepsy
- 5 October 2025
- Published by Elsevier in Neuroscience
- Vol. 588, 84-91
Choroid plexus enlargement correlates with cognitive impairment and brain atrophy in patients with temporal lobe epilepsy
- 18 January 2025
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 13 (8) , 2810-2819
Nanoparticles modified with glucose analogs to enhance the permeability of the blood–brain barrier and their accumulation in the epileptic brain
Drug delivery for epilepsy treatment faces enormous challenges, where the sole focus on enhancing the ability of drugs to penetrate the blood–brain barrier (BBB) through ligand modification is insufficient because of the absence of seizure-specific drug accumulation. In this study, an amphipathic drug carrier with a glucose transporter (GLUT)-targeting capability was synthesised by conjugating 2-deoxy-2-amino-D-glucose (2-DG) to the model carrier DSPE-PEG2k. A 2-DG-modified nano drug delivery system (NDDS) possessing robust stability and favourable biocompatibility was then fabricated using the nanoprecipitation method. The results showed that the 2-DG-modified NDDS exhibited enhanced cellular uptake by brain capillary endothelial cells and neuronal cells. Most importantly, the 2-DG-modified NDDS exhibited enhanced BBB penetration and brain accumulation, especially in the epileptic brain, thus achieving seizure-based on-demand drug delivery. Our study provides a simple and smart strategy for the delivery of anti-seizure medicines.
- 18 January 2025
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 13 (8) , 2810-2819
Nanoparticles modified with glucose analogs to enhance the permeability of the blood–brain barrier and their accumulation in the epileptic brain
Drug delivery for epilepsy treatment faces enormous challenges, where the sole focus on enhancing the ability of drugs to penetrate the blood–brain barrier (BBB) through ligand modification is insufficient because of the absence of seizure-specific drug accumulation. In this study, an amphipathic drug carrier with a glucose transporter (GLUT)-targeting capability was synthesised by conjugating 2-deoxy-2-amino-D-glucose (2-DG) to the model carrier DSPE-PEG2k. A 2-DG-modified nano drug delivery system (NDDS) possessing robust stability and favourable biocompatibility was then fabricated using the nanoprecipitation method. The results showed that the 2-DG-modified NDDS exhibited enhanced cellular uptake by brain capillary endothelial cells and neuronal cells. Most importantly, the 2-DG-modified NDDS exhibited enhanced BBB penetration and brain accumulation, especially in the epileptic brain, thus achieving seizure-based on-demand drug delivery. Our study provides a simple and smart strategy for the delivery of anti-seizure medicines.